OBJECTIVES: This study sought to evaluate the risk of cancer in patients with heart failure (HF) compared with community controls and to determine the impact of cancer post-HF on outcomes. BACKGROUND: HF is associated with excess morbidity and mortality. Noncardiac causes of adverse outcomes in HF are increasingly recognized, but not fully characterized. METHODS: In a case-control study, we compared the history of cancer among community subjects newly diagnosed with HF from 1979 to 2002 to age-, sex-, and date-matched community controls without HF (961 pairs). Individuals without cancer at the index date (596 pairs) were followed for cancer in a cohort design, and the survival of HF patients who developed cancer was assessed. RESULTS: Before the index date, 22% of HF cases and 23% of controls had a history of cancer (odds ratio [OR]: 0.94; 95% confidence interval [CI]: 0.75 to 1.17). During 9,203 person-years of follow-up (7.7 ± 6.4 years), 244 new cancer cases were identified; HF patients had a 68% higher risk of developing cancer (hazard ratio [HR]: 1.68; 95% CI: 1.13 to 2.50) adjusted for body mass index, smoking, and comorbidities. The HRs were similar for men and women, with a trend toward a stronger association among subjects ≤75 years of age (p = 0.22) and during the most recent time period (p = 0.075). Among HF cases, incident cancer increased the risk of death (HR: 1.56; 95% CI: 1.22 to 1.99) adjusted for age, sex, index year, and comorbidities. CONCLUSIONS: HF patients are at increased risk of cancer, which appears to have increased over time. Cancer increases mortality in HF, underscoring the importance of noncardiac morbidity and of cancer surveillance in the management of HF patients.
OBJECTIVES: This study sought to evaluate the risk of cancer in patients with heart failure (HF) compared with community controls and to determine the impact of cancer post-HF on outcomes. BACKGROUND: HF is associated with excess morbidity and mortality. Noncardiac causes of adverse outcomes in HF are increasingly recognized, but not fully characterized. METHODS: In a case-control study, we compared the history of cancer among community subjects newly diagnosed with HF from 1979 to 2002 to age-, sex-, and date-matched community controls without HF (961 pairs). Individuals without cancer at the index date (596 pairs) were followed for cancer in a cohort design, and the survival of HF patients who developed cancer was assessed. RESULTS: Before the index date, 22% of HF cases and 23% of controls had a history of cancer (odds ratio [OR]: 0.94; 95% confidence interval [CI]: 0.75 to 1.17). During 9,203 person-years of follow-up (7.7 ± 6.4 years), 244 new cancer cases were identified; HF patients had a 68% higher risk of developing cancer (hazard ratio [HR]: 1.68; 95% CI: 1.13 to 2.50) adjusted for body mass index, smoking, and comorbidities. The HRs were similar for men and women, with a trend toward a stronger association among subjects ≤75 years of age (p = 0.22) and during the most recent time period (p = 0.075). Among HF cases, incident cancer increased the risk of death (HR: 1.56; 95% CI: 1.22 to 1.99) adjusted for age, sex, index year, and comorbidities. CONCLUSIONS: HF patients are at increased risk of cancer, which appears to have increased over time. Cancer increases mortality in HF, underscoring the importance of noncardiac morbidity and of cancer surveillance in the management of HF patients.
Authors: M Pahor; J M Guralnik; L Ferrucci; M C Corti; M E Salive; J R Cerhan; R B Wallace; R J Havlik Journal: Lancet Date: 1996-08-24 Impact factor: 79.321
Authors: Véronique L Roger; Susan A Weston; Margaret M Redfield; Jens P Hellermann-Homan; Jill Killian; Barbara P Yawn; Steven J Jacobsen Journal: JAMA Date: 2004-07-21 Impact factor: 56.272
Authors: Tal Hasin; Yariv Gerber; Susan A Weston; Ruoxiang Jiang; Jill M Killian; Sheila M Manemann; James R Cerhan; Véronique L Roger Journal: J Am Coll Cardiol Date: 2016-07-19 Impact factor: 24.094
Authors: Binyamin Ben Avraham; Marisa Generosa Crespo-Leiro; Gerasimos Filippatos; Israel Gotsman; Petar Seferovic; Tal Hasin; Luciano Potena; Davor Milicic; Andrew J S Coats; Giuseppe Rosano; Frank Ruschitzka; Marco Metra; Stefan Anker; Johann Altenberger; Stamatis Adamopoulos; Yaron D Barac; Ovidiu Chioncel; Nicolaas De Jonge; Jeremy Elliston; Maria Frigeiro; Eva Goncalvesova; Avishay Grupper; Righab Hamdan; Yoav Hammer; Loreena Hill; Osnat Itzhaki Ben Zadok; Miriam Abuhazira; Jacob Lavee; Wilfried Mullens; Sanemn Nalbantgil; Massimo F Piepoli; Piotr Ponikowski; Arsen Ristic; Arjang Ruhparwar; Aviv Shaul; Laurens F Tops; Steven Tsui; Stephan Winnik; Tiny Jaarsma; Finn Gustafsson; Tuvia Ben Gal Journal: ESC Heart Fail Date: 2021-09-14
Authors: Douglas J Leedy; Kerryn W Reding; Alexi L Vasbinder; Garnet L Anderson; Ana Barac; Jean Wactawski-Wende; Aladdin H Shadyab; Charles B Eaton; Wayne C Levy; LiHong Qi; Richard K Cheng Journal: Eur J Heart Fail Date: 2021-06-06 Impact factor: 17.349
Authors: Texali C Garcia-Garduño; Jorge R Padilla-Gutierrez; Diego Cambrón-Mora; Yeminia Valle Journal: Int J Mol Sci Date: 2021-07-01 Impact factor: 5.923
Authors: Rudolf A de Boer; Joseph Pierre Aboumsallem; Valentina Bracun; Douglas Leedy; Richard Cheng; Sahishnu Patel; David Rayan; Svetlana Zaharova; Jennifer Rymer; Jennifer M Kwan; Joshua Levenson; Claudio Ronco; Paaladinesh Thavendiranathan; Sherry-Ann Brown Journal: Cardiooncology Date: 2021-06-21